BioNTech to terminate mid-stage trial of mRNA cancer vaccine

BioNTech decided to terminate its mid-stage mRNA-based cancer vaccine trial for a specific type of colorectal cancer, and its U.S.-listed shares fell nearly 9%. The decision signals a setback in clinical development for the program, likely increasing uncertainty around timelines and future pipeline value. Near-term investor sentiment is likely to remain cautious as the company reassesses its oncology strategy.